ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Blood Cell-Camouflaged Liquid Metal Nanoconjugates Orchestrate Treg Depletion and STING-Amplified Photothermal Immunity for Metastatic Triple-Negative Breast Cancer Therapy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Triple-negative breast cancer (TNBC) remains highly lethal due to aggressive metastasis and profound immunosuppression by regulatory T cells (Tregs). Here, we present a biomimetic liquid metal (LM)-based photothermal immunotherapeutic nanoplatform exploiting gallium-based LMs to orchestrate cascade amplification of antitumor immunity. The engineered nanoplatform (B-LM-DMX-αCD25) integrates an LM photothermal core with dual immunomodulatory components-anti-CD25 antibody for Treg depletion and stimulator of interferon genes (STING) agonist 5,6-dimethylxanthenone-4-acetic acid (DMX) for innate immune activation-while blood-derived camouflaging enhances immune evasion and tumor accumulation. Quantitative RT-PCR of 13 immune-related genes confirmed STING engagement, robust CD8+ cytotoxic T-cell infiltration, and Treg depletion in treated tumors. This platform operates through three synchronized mechanisms: (1) selective intratumoral Treg depletion dismantling immunosuppression; (2) near-infrared-triggered LM-mediated photothermal therapy (58°C within 5 min) inducing immunogenic cell death and releasing tumor-associated antigens; and (3) STING pathway activation promoting dendritic cell maturation and tumor-specific cytotoxic T-cell responses, collectively transforming immunologically "cold" TNBC into immune-responsive tumors. In orthotopic 4T1 models, the nanoplatform achieves significant tumor regression with enhanced survival, while in metastatic models, it reduces pulmonary metastatic nodules and extends median survival beyond 70 days. This work establishes a paradigm-shifting biomimetic LM-based nanodelivery strategy addressing fundamental immunological barriers in TNBC through coordinated photothermal-immunotherapy, offering a clinically translatable approach for TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.